ARTICLE | Financial News
Cancer play Rgenix raises $33M
June 16, 2016 1:20 AM UTC
Rgenix Inc. (New York, N.Y.) raised $33 million in a series B round led by new investors Novo A/S (Hellerup, Denmark) and Sofinnova Partners. Existing investors including Partnership Fund for New York City, Alexandria Venture Investments and Conegliano Ventures also participated.
Next half, Rgenix plans to start Phase I testing of RGX-104 in multiple cancers including melanoma, non-small cell lung cancer (NSCLC) and ovarian cancer. Rgenix in-licensed the small molecule inhibitor of liver X receptor beta ( NR1H2; LXR-b) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), where it had been in preclinical development for cardiovascular disease. ...